Micro
Aftermath
Archived
BVF trims MoonLake stake, sells $63M in shares
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
11
Sources
2
Top Movers
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Related Articles
Why This Fund Sold $11 Million of BILL Stock Despite a $1 Billion Buyback Plan
Nasdaq
·
May 24, 2026
BIT Capital Dumps 1.24 Million Lemonade (LMND) Shares Worth $86 Million
Nasdaq
·
May 17, 2026
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge
Nasdaq
·
May 08, 2026
North of South Dumps $38.5 Million Vipshop Stake -- What Investors Should Know
Nasdaq
·
Apr 20, 2026
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Nasdaq
·
Apr 18, 2026
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
Nasdaq
·
Apr 07, 2026
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Technology | +43.3% | |
| Technology | +41.7% | |
| Financials | +24.1% | |
| Industrials | +24.0% | |
| Financials | +20.9% |
🤖
AI Overview
PARAGRAPH 1 --- On May 15, 2026, BVF Partners L.P., a biotech-focused fund, sold 3,750,000 shares of MoonLake Immunotherapeutics (NASDAQ:MLK), an estimated $62.96 million transaction based on quarterly average pricing. This sale represented 78.30% of BVF's direct holdings, reducing its direct ownership to 1,039,238 shares.
PARAGRAPH 2 --- The sale by BVF, a significant shareholder, could put downward pressure on MoonLake's stock price due to increased supply. This could also signal a shift in BVF's strategy, potentially impacting other biotech stocks in their portfolio.
PARAGRAPH 3 --- Next, investors should watch MoonLake's upcoming earnings release on July 15, 2026, and any further SEC filings from BVF to understand if this sale is part of a broader strategy change. Additionally, the market's reaction to this sale will be crucial in determining the stock's short-term trajectory.
PARAGRAPH 2 --- The sale by BVF, a significant shareholder, could put downward pressure on MoonLake's stock price due to increased supply. This could also signal a shift in BVF's strategy, potentially impacting other biotech stocks in their portfolio.
PARAGRAPH 3 --- Next, investors should watch MoonLake's upcoming earnings release on July 15, 2026, and any further SEC filings from BVF to understand if this sale is part of a broader strategy change. Additionally, the market's reaction to this sale will be crucial in determining the stock's short-term trajectory.
AI Overview as of May 30, 2026
Timeline
First SeenApr 07, 2026
Last UpdatedApr 07, 2026